Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities.

Cancer letters - 8 May 2003

Jang Young-Ju, Park Kill Soon, Chung Hee-Yong, Kim Hyung-Il

Abstract excerpt

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to exert potent cytotoxic activity against many tumor cells but not normal cells. However, some tumor cells are resistant to TRAIL, and it has not been determined how this occurs. In the present study, we obtained three subgroups of Jurkat clones with TRAIL-sensitive, -partial resistant and -resistant phenotypes. We found that most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 8
Share to Caspase 9
Share to Coloring Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Acid Desaturases

Share to Receptor-Interacting Protein Serine-Threonine Kinases

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Tetrazolium Salts

Share to TNF-Related Apoptosis-Inducing Ligand

Source

Identifiers

PMID: 12706864
DOI: 10.1016/s0304-3835(02)00680-8

Genes

FADD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities.PMID 12706864Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1.Semantic proximity Read ↗

Involvement of DR4/JNK pathway-mediated autophagy in acquired TRAIL resistance in HepG2 cellsSemantic proximity Read ↗

TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways.Semantic proximity Read ↗

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.Semantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

Mechanisms of resistance to TRAIL-induced apoptosis in cancer.Semantic proximity Read ↗

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.Semantic proximity Read ↗

Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis.Semantic proximity Read ↗

Dexamethasone induces apoptosis in human T cell clones expressing low levels of Bcl-2.Semantic proximity Read ↗

Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatinSemantic proximity Read ↗

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.